Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 2/3 1

Status

Recruiting 7Not yet recruiting 5Completed 2Withdrawn 1Unknown 1Terminated 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Pancreatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Esophageal Squamous Cell Carcinoma 5Triple Negative Breast Neoplasms 3Neoplasms 3Head and Neck Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Thymoma 1Thymic epithelial tumor 1Squamous NSCLC 1Small Cell Lung Carcinoma 1Salivary Gland Malignant Neoplasms 1Pathologic Complete Response 1Pancreatic cancer, adult 1Pancreatic Cancer Resectable 1Melanoma 1Mediastinal Neoplasms 1Locally Advanced Non-Small Cell Lung Cancer 1Gastric Adenocarcinoma 1Fallopian Tube Neoplasms 1Esophageal Squamous Carcinoma 1Carcinoma 1Brain Neoplasms 1Anophthalmia with pulmonary hypoplasia 1Advanced Triple Negative Breast Cancer 1

Interventions

toripalimab 6Cisplatin 5130-nm albumin-bound paclitaxel 5Drug Therapy 4tislelizumab 3sintilimab 3camrelizumab 3Injections 3Immune Checkpoint Inhibitors 3Fluorouracil 3Carboplatin 3nedaplatin 2anlotinib 2Radiotherapy 2Paclitaxel 2Neoadjuvant Therapy 2Irinotecan 2Esophagectomy 2potassium oxonate 1pembrolizumab 1lenvatinib 1ivarmacitinib 1irinotecan sucrosofate 1Watchful Waiting 1Taxes 1TP protocol 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiation 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × Esophageal Squamous Cell Carcinoma × 130-nm albumin-bound paclitaxel × Clear all
NCT06861894 2025-05-15

Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC

Shanghai Chest Hospital

Phase 2 Not yet recruiting
164 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06861777 2025-03-11

Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2/3 Not yet recruiting
474 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06388135 2024-04-29

Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Xijing Hospital

Phase 4 Not yet recruiting
80 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06178211 2023-12-20

Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial

Shanghai Chest Hospital

Phase 2 Not yet recruiting
36 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05896787 2023-06-09

Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
45 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡